Cellectar Biosciences Shares Higher

Cellectar Biosciences Shares Higher

Cellectar Biosciences gained 7% in morning trade Tuesday after its phospholipid drug conjugate research program generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone in tumor treatment. Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company’s PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that […]

Read More ˃